Why ACE Inhibitors produce dry cough and why the pregnant women should not take ACE Inhibitors pharmacology
Reading File
Finding Sources
Finding Sources
Searching PubMed
ACE inhibitor cough bradykinin mechanism
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive, authoritative information from top textbooks. Here is the full, detailed answer:
ACE Inhibitors: Dry Cough and Pregnancy Contraindication
Part 1 - Why ACE Inhibitors Cause Dry Cough
The Core Mechanism: Bradykinin Accumulation
ACE (Angiotensin-Converting Enzyme) is a dual-function enzyme. It has two main jobs:
- Convert angiotensin I → angiotensin II (vasopressor effect)
- Break down (inactivate) bradykinin - a vasodilator peptide (ACE is also called kinase II)
When you block ACE with an ACE inhibitor (e.g., enalapril, lisinopril, ramipril), you block both functions simultaneously. The intended benefit is reduced angiotensin II (lower BP, less vasoconstriction). The side effect comes from the second function being blocked: bradykinin is no longer degraded and accumulates in the tissues.
How Bradykinin Accumulation Triggers Cough
Bradykinin and another tachykinin called substance P both accumulate when ACE is inhibited. These mediators:
- Directly sensitize sensory C-fiber nerve endings in the bronchial mucosa and airways (the afferent arm of the cough reflex)
- Stimulate prostaglandin synthesis (via arachidonic acid pathway), which further sensitizes cough receptors
- Lower the cough reflex threshold, making the airways hypersensitive
The result is a dry, non-productive, persistent cough - classically described as a "tickle in the throat." Patients with ACE inhibitor cough also show an enhanced response to capsaicin inhalation challenge (a validated test for airway cough sensitivity), confirming the sensory sensitization mechanism.
- Harrison's Principles of Internal Medicine 22E, p. 2274
- Goldman-Cecil Medicine, ACE Inhibitors and ARBs section
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
Key Clinical Facts About the Cough
| Feature | Detail |
|---|---|
| Incidence | 5-30% of patients on ACE inhibitors |
| Character | Dry, non-productive, irritating tickle |
| Dose dependence | NOT dose-dependent - does not improve with dose reduction |
| Onset | Can appear weeks to months after starting |
| Gender | More common in women and in East Asian populations |
| Resolution | Resolves within days to weeks of stopping the drug |
| Test for it | If cough doesn't improve 1 month after stopping, ACE inhibitor is NOT the cause |
Why ARBs Don't Cause Cough
ARBs (e.g., losartan, valsartan) block the AT1 receptor but do not inhibit kinase II (ACE). Therefore, bradykinin metabolism is unaffected - bradykinin is still normally broken down. This is why ARBs are the go-to substitute when ACE inhibitors cause cough.
- Goldman-Cecil Medicine - "ARBs do not inhibit kinase II or the breakdown of bradykinin, so they do not cause cough."
- The Washington Manual of Medical Therapeutics - "In contrast to ACE inhibitors, ARBs do not increase bradykinin levels and therefore are not associated with cough."
Part 2 - Why ACE Inhibitors Are Contraindicated in Pregnancy
Overview
ACE inhibitors are absolutely contraindicated in the 2nd and 3rd trimesters of pregnancy, and recent evidence also implicates 1st trimester exposure as increasing teratogenic risk (Katzung 16th Ed.). Both ACE inhibitors and ARBs share this contraindication.
The Mechanism - Fetal Renin-Angiotensin System Dependence
The critical point is that the fetal kidney and cardiovascular system are entirely dependent on the renin-angiotensin system (RAS) for normal development, especially for:
- Maintaining fetal renal perfusion pressure
- Driving glomerular filtration and urine production
- Regulating amniotic fluid volume (since fetal urine is the main source of amniotic fluid after 16 weeks)
When an ACE inhibitor crosses the placenta and reaches the fetus, it blocks fetal angiotensin II, causing:
The ACE Inhibitor Fetopathy - Step by Step
ACE inhibitor crosses placenta
↓
Fetal angiotensin II suppressed
↓
↓ Fetal renal perfusion pressure
↓
Fetal renal hypoperfusion → Renal tubular dysplasia / Renal failure
↓
↓ Fetal urine output
↓
OLIGOHYDRAMNIOS (insufficient amniotic fluid)
↓
Compression of fetus by uterine walls
↓
Hypocalvaria (underdeveloped skull bones)
Limb contractures, pulmonary hypoplasia
Intrauterine growth restriction (FGR)
Fetal demise
Summary of Fetal Effects (ACE Inhibitor Fetopathy)
| Fetal/Neonatal Effect | Mechanism |
|---|---|
| Fetal hypotension | Loss of angiotensin II-mediated vascular tone |
| Renal tubular dysplasia | Hypoperfusion injury to developing nephrons |
| Oligohydramnios | Reduced fetal urine output (main source of amniotic fluid) |
| Anuria / renal failure in neonate | Sustained renal ischemia |
| Hypocalvaria (soft skull) | Compression from oligohydramnios |
| Fetal growth restriction (FGR) | Poor perfusion, physical compression |
| Fetal/neonatal death | Combined effects of all above |
- Creasy & Resnik's Maternal-Fetal Medicine - "ACE inhibitor fetopathy including oligohydramnios, FGR, hypoplasia of the calvaria, renal dysplasia, anuria, renal failure, and fetal demise."
- Katzung's Basic and Clinical Pharmacology, 16th Ed. - "Contraindicated during the second and third trimesters because of the risk of fetal hypotension, anuria, and renal failure, sometimes associated with fetal malformations or death."
Why the 2nd and 3rd Trimesters Are Especially Dangerous
The fetal kidneys begin producing urine around weeks 11-16, and from the 2nd trimester onward, fetal urine is the primary source of amniotic fluid. Once oligohydramnios sets in, the cascade of physical compression effects (lung hypoplasia, limb deformities, skull abnormalities) becomes very severe. This is why 2nd and 3rd trimester exposure carries the highest risk.
First trimester exposure is also now implicated in cardiac malformations and increased teratogenic risk overall.
Safe Alternatives in Pregnancy
| Condition | Safe antihypertensive in pregnancy |
|---|---|
| Hypertension | Methyldopa, labetalol, nifedipine |
| Heart failure | Beta-blockers, hydralazine + nitrates |
| ANY indication | Never ACE inhibitors or ARBs |
Quick Summary Table
| Feature | ACE Inhibitor Cough | ACE Inhibitor in Pregnancy |
|---|---|---|
| Cause | Bradykinin + substance P accumulation | Blocks fetal RAS; suppresses fetal Ang II |
| Mechanism | Sensory C-fiber sensitization in airways | Fetal renal hypoperfusion → oligohydramnios cascade |
| Key mediator | Bradykinin (and prostaglandins) | Angiotensin II (fetal dependent) |
| Incidence | 5-30% of users | Affects nearly all exposed fetuses in 2nd/3rd trimester |
| Management | Switch to ARB (no bradykinin effect) | Stop ACE inhibitor; switch to safe antihypertensive |
| ARB comparison | ARBs do NOT cause cough | ARBs carry the same fetal risk |
This is a shared conversation. Sign in to Orris to start your own chat.